Pharmaceutical Department

2017

Annual Report

St. Jude Children's
Research Hospital

ALSAC • Danny Thomas, Founder

Finding cures. Saving children.

2017 Annual Report
Pharmaceutical Department

Faculty: Full Members: William E. Evans, PharmD; William Greene, PharmD; Mary V. Relling, PharmD (chair); Erin G. Schuetz, PhD; John D. Schuetz, PhD (vice-chair), Clinton F. Stewart, PharmD; Associate Members: James M. Hoffman, PharmD; Jun J. Yang, PhD; Assistant Members: Daniel Savic, PhD; Liqin Zhu, PhD

Laboratory Directors: Alejandro Molinelli, PhD; Kristine R. Crews, PharmD

Fellows: Jordan Beard, PhD; Rebba Boswell-Casteel, PhD; Christopher Coke, PhD; Rebecca Crawford, PhD; Jonathan Diedrich, PhD; Daniel Ferguson, PhD; Emily Finch, PhD; Yoshihiro Gocho, MD, PhD; Tomoka Gose, PhD; Laura Hamel, PhD; Charnise Goodings-Harris, PhD; Zachary Jones, PhD; Yizhen Li, PhD; Chengcheng Liu, PhD; Yiwei Liu, PhD; Anil Maharaj, PhD; Robert McCorkle, PhD; Takaya Moriyama, MD, PhD; Maoxiang Qian, PhD; Juwina Wijaya, PhD; Hui Zhang, MD, PhD

Residents: Philip Carpiniello, PharmD; Kelsey Hyman, PharmD; Arathi Lambrix, PharmD; Cameron Thomas, PharmD

Graduate Students: Kavya Annu, R.J.Autry, Alessio Cozzarolo, Ashley Crumby, Samit Ganguly, Jianzhong Hu, Chuang Jiang, Nick Keeling, Xujie Zhao, Chan Zou

Computational Staff: Nancy Kornegay**,** Andrey Matlin, Carl Panetta, PhD; Colton Smith, Austin Springer, Wenjian Yang

Staff Scientists: Barthelemy Diouf, PhD; Amarjit Chaudhry, PhD; John Lynch, PhD; Yu Fukuda, PhD

Pharmacist leadership: David Aguero, PharmD; Delia Carias, PharmD; Wendell Cheatham, DPh; William Humphrey, DPh, MS, MBA; John McCormick, PharmD; Steve Pate, DPh; Jennifer Pauley, PharmD; Jennifer Robertson, PharmD; Barry Williams, BS Pharm

Clinical Pharmacy Specialists: Liz Hall, PharmD; PJ Barker, PharmD; Allison Bragg, PharmD; Andy Christensen, PharmD; Richard Clark, PharmD; Shane Cross, PharmD; Clay Daniels, PharmD; Melissa Quinn, PharmD; Hope Swanson, PharmD; Deborah Ward, PharmD

Pharmacists: Chris Askins, PharmD; Monica Bant, PharmD; James Bryant, BS Pharm; Susan Carr, PharmD; Robbin Christensen, DPh; Monty Coleman, BS Pharm; Hana Danzi, MS Pharm; Nousheen DeRenzo, PharmD; Debra Ethridge, PharmD; Joseph Evans, PharmD; Liz Gallimore, PharmD; Amy Harris, PharmD; Kelsey Hyman, PharmD; Timothy Jacobs, PharmD; Jennifer Kemper, PharmD; Jenny Knych, PharmD; Arathi Lambrix, PharmD; Chuck Longserre, PharmD; Linda Marden, DPh; Shane Marshall, PharmD; Jennifer Mason, PharmD; Anne McCormick, BS Pharm; Tommy Mills, PharmD; James Moore, BS Pharm; Tiffany Nason, PharmD; Tanya Nguyen, PharmD; Trina Peery, PharmD; Jackie Quackenbush, BS Pharm; Julie Richardson, PharmD; Linda Schiff, PharmD; Chris Scobey, PharmD; Camille Smith, PharmD; Kevin Smith, PharmD; Tabetha Todd, PharmD; Deni Trone, PharmD, Dagny Ulrich, PharmD, Gayle Westmoreland, BS Pharm; Cheri Wilkerson, PharmD, Elizabeth Wilson, PharmD; Matthew Wilson, PharmD; Curtis Yeh, PharmD; Keith Young, PharmD

Overview:

The primary goal of Pharmaceutical Sciences is to improve therapy for children with catastrophic diseases by elucidating the basis for interpatient variability in response to medications. Survival rates for children with cancer, hematologic disorders, HIV infection, or other serious diseases continue to increase, largely through the improved use of medications. Failure of current therapies and unacceptable adverse effects are partly due to less-than optimal prescribing. Our goal is to elucidate the biological basis of interindividual differences in pharmacologic response, and to translate our findings into improving patient care.

Heterogeneity in the metabolism, transport, elimination, targets, and receptors of many drugs and consequent variability in therapeutic or adverse effects may result from germline genetic differences or genetic alterations in malignant cells. Drug response is also influenced by nongenetic factors (e.g., drug interactions, host organ function and maturity, disease severity, adherence to therapy).
We develop preclinical models to systematically characterize the determinants of human variation in drug response, and we integrate our work into translational clinical studies (Figure 1). Laboratory work informs clinical studies, and clinical problems drive much of the laboratory work.

Figure 1. With responsibility for medications, the use of clinical data, and the development of clinical and research laboratory tests, knowledge is used to provide the best possible care for St. Jude patients while making discoveries with implication outside of St. Jude.

Faculty members lead and participate in interdisciplinary St. Jude programs and national cooperative research collaborations. Our pharmacogenetic research integrates genome-wide analyses, molecular analyses, functional genomics, pharmacokinetics, and pharmacodynamics to identify genetic determinants of drug effects, with the long- term goal of optimizing therapy for individual patients. The Department comprises both Pharmaceutical Sciences and Pharmaceutical Services, and includes ten faculty members, 15-25 post-doctoral fellows (Figure 2) and residents (Figure 9), 10-20 undergraduate and graduate students, over 45 pharmacists, and over 110 full time staff members working as computing experts, research nurses, technical, laboratory, administrative, and clinical staff. The department is supported by multiple NIH grants. The research in the department includes clinical and fundamental

Figure 2. Post-doctoral fellows 2016-2017 **Back row**: *Maxoxiang Qian, Yizhen Li, Christopher Coke, Jonathan Diedrich , Charnise Goodings Harris, Daniel Ferguson, and Jordan Beard.* **Front row**: *Tomoko Gose, Juwina Wijaya, Rebecca Crawford, Takaya Moriyama, Laura Hamel, Yiwei Liu, Emily Finch, Zachary Jones, and Anil Maharaj.*

pharmacology, pharmacokinetics, pharmacodynamics, and pharmacogenomics. Pharmaceutical Sciences occupies over 15,000 sq. ft. of contiguous state-of-the-art equipped laboratory and office space, and Pharmaceutical Services occupies over 18,000 square feet of space in the clinical areas of St. Jude. The department hosts weekly research workshops and journal clubs that are open to the entire institution and are widely attended by colleagues outside the department, in addition to multiple laboratory or Services specific meetings, webinars with national and international colleagues, and regular pharmacogenomics meetings.

Details on the rich St. Jude environment for clinical care and for clinical and basic research are available at www.stjude.org.

Pharmaceutical Department faculty, staff, and trainees work closely with each other; with our collaborators in other departments at St. Jude; and with colleagues around the world on basic translational, and clinical research projects and to provide outstanding pharmaceutical care to St. Jude patients.

Faculty:

William E. Evans, PharmD

Research in the Evans lab is focused on the pharmacogenomics of anticancer agents, with an emphasis on childhood acute lymphoblastic leukemia (ALL) (reviewed in Evans and Relling, *Nature* 2004; Pui and Evans, *NEJM* 2006; Paugh et al, *Clin Pharmacol Ther* 2011; Relling and Evans, *Nature* 2015). Several approaches are currently being used to identify genes and genome variations that are important determinants of the disposition and effects of antileukemic agents, including the use of genome wide approaches such as gene expression profiling (mRNA, microRNA) of leukemia cells, genome-wide SNP analyses (germline and somatic) and whole exome/genome sequencing of patient cohorts that have been uniformly treated and evaluated on prospective clinical trials at St. Jude

Figure 3: CASP1 causes glucocorticoid resistance via glucocorticoid receptor cleavage. We are building on our prior discovery that increased expression of inflammasome components CASP1 and NLRP3 via somatic hypo-methylated promoter regions in leukemia cells leads to glucocorticoid receptor cleavage by CASP1 and glucocorticoid (GC) resistance (see Paugh et al, Nature Genet 2015). We have now found evidence that this mechanism of GC resistance is operative in leukocytes of patients with chronic kidney disease who are refractory to GC treatment. We have more recently found a higher frequency of GC resistance in adult ALL, and are investigating whether the CASP1 mechanism is responsible. We are also pursuing high-throughput screens to identify small molecule inhibitors of CASP1 as a strategy to mitigate this mechanism of GC resistance, and enhance treatment response.

Children's Research Hospital (reviewed in Evans and Relling, *Nature* 2004), or by our collaborators in the COG and in Europe (e.g. Princess Maxima Center, Utrecht). Ongoing studies are investigating genes that the lab has linked with resistance to antileukemic agents (Figure 3) (Holleman et al, *NEJM* 2004; Lugthart et al, *Cancer Cell* 2005), and genes linked to the disposition (Kager et al, *JCI* 2005; Zaza, *Blood* 2005) or pharmacologic targets (Diouf et al, *JAMA* 2015; Paugh et al, *Nat Genet* 2015) of antileukemic agents as well as the influence of somatic and karyotypic abnormalities on genotype-phenotype concordance (Cheng, *Nature Genetics* 2005; Diouf et al, *Nature Med* 2011). Work in the lab is funded by a long-standing R01 from NCI (CA36401, W. Evans, PI), a project in the Center for Precision Medicine P50 Grant from NIGMS as part of the NIH-funded Pharmacogenetics Research Network (GM115279, M. Relling PI), by a Cancer Center Support grant from NCI (CA21765 C. Roberts, PI), and by ALSAC, the fundraising organization for St. Jude Children's Research Hospital. The lab comprises a number of post-doctoral fellows, staff scientists, research technologists, bioinformaticists, computational scientists and students, working with collaborators at St. Jude (including Mary Relling, Ching-Hon Pui, Charles Mullighan, K. Roberts, Hiroto Inaba, Kirsten Ness and

Jun J. Yang as major collaborators, plus additional physicians, clinical pharmacists, research nurses and other staff at St. Jude), and with collaborators at other institutions in the US (HudsonAlpha, University of Chicago) and Europe (Erasmus University, Princess Maxima Center). The lab's overall goals are to elucidate genomic determinants of toxicity and efficacy of anticancer agents and translate this knowledge into new diagnostics and treatment strategies to optimize the therapy of ALL (Relling and Evans, *Nature* 2015; Dunnenberger et al, *Ann Rev Pharmacol Tox* 2015).

William Greene, PharmD

I joined Pharmaceutical Services as Chief Pharmaceutical Officer in August 2007. I have had a long career as a clinical pharmacy practitioner and leader in development of drug policy in hospital- based practice. My interests have been diverse and are summed up in the goal of developing structures, personnel, policy and practice to accomplish the best possible system to assure optimal outcomes of pharmacotherapy. My interests in infectious diseases, pharmacokinetics, performance improvement and medication safety continue.

As the senior leader of Pharmaceutical Services, it is my goal to assure the best possible design and function of pharmacy services to assure that we achieve the desired outcomes of drug therapy for St. Jude patients. To this end, Pharmaceutical Services collaborates closely with other disciplines in providing patient care, and with clinicians and scientists in translational and clinical research, and employs the principles of continuous process improvement in ongoing refinement/improvement of patient-related services. Clinical research in Pharmaceutical Services focuses on applying pharmacokinetic, pharmacogenetic, and therapeutic drug monitoring principles to patient care, and in improving the safety of medication use. I currently retain a faculty appointment with the University of Tennessee College of Pharmacy (Professor, Affiliated), and am active in national and state professional organizations (American College of Clinical Pharmacy, American Society of Health Care Systems Pharmacists, and Tennessee Pharmacists Association).

James M. Hoffman, Pharm

I joined the Pharmaceutical Department in 2004, and the St. Jude Faculty in 2011. My career has focused on evaluating and improving complex medication use systems, and I currently provide leadership to evaluate and improve a range of patient care processes through my role as the hospital's Chief Patient Safety Officer within the Office of Quality and Patient Care. My research is focused on patient safety event detection, patient safety culture, and clinical decision support.

Our work on patient safety event detection and reporting systems is built on our department's leadership to develop and implement St. Jude's novel electronic event reporting system software (EERS). EERS is used to report all patient safety events at St. Jude, and this system has resulted in a 20% increase in event reporting. Because a healthy patient safety culture is essential to safe care, we have focused on assessing patient safety culture at St. Jude and devised new tools to measure specific aspects of safety culture in the hospital setting (Petschonek S et al *J Patient Saf 2014* and Burlison JD et al *J Patient Saf 2014*).

I also lead a variety of efforts to expand and improve the use of clinical decision support (CDS) in the electronic health record (EHR). Through the PG4KDS protocol, St. Jude is a leader in incorporating pharmacogenetic data and associated CDS into the EHR (Bell et al, JAMIA, 2013; Hicks et al AJHP, 2016) (Figure 4), and I have contributed to this protocol as an investigator since its inception. I have also been actively engaged in the Clinical Pharmacogenetic Implementation Consortium (CPIC) since its inception, and I co-lead the CPIC Informatics Working Group. CPIC has devised vendor agnostic implementation resources which are available for each guideline (Hoffman et al. *JAMIA*, 2016). CPIC also recently lead a consensus process to standardize pharmacogenetic terms, which is being widely adopted and will help facilitate sharing pharmacogenetic results across disparate clinical information systems. (Caudle et al. *Genet Med*. 2016) More recently, we have studied payer perspectives on pre-emptive pharmagenetics to understand how to improve reimbursement for pharmacogenetic testing. (Keeling et al. *Genet Med.* 2017)

Figure 4. Post-test alerts interrupt clinicians to change prescribing only when a high-risk drug is ordered for a patient with a high-risk pharmacogenetic phenotype. Clinical implementation of pharmacogenetic tests is part of the medication safety program for St. Jude (Hicks et al, AJHP, 2016).

Mary V. Relling, PharmD

I have been a faculty member in the Pharmaceutical Department at St. Jude since 1988 and chair of the department since 2003. The majority of my discovery research efforts have been directed to translational research in childhood acute lymphoblastic leukemia (ALL), to identify the host- and treatment-related risk factors for adverse treatment outcomes in ALL. I also maintain clinical involvement at St. Jude and in the Children's Oncology Group (COG). The clinical problems faced by children with ALL drive my research. Much of the work of my laboratory focuses on finding the genetic basis of why patients differ from one another in their risk of adverse effects of therapy, both drug toxicities and ALL relapse. I co-lead the Center for Precision Medicine in Leukemia (CPML), a multidisciplinary research group (http://www.pgrn.org/precision-medicine-in-leukemia.html). We also study how non-genetic factors (e.g., diet and drug interactions, kidney and liver function, and age) affect how patients differ from each other in response to medications.

The ALL phenotypes we focus on most include relapse, glucocorticoid induced osteonecrosis (Figure 5), asparaginase immunogenicity and pharmacodynamics, and hepatotoxicity (e.g. Liu C et al, *JCO,*

2016; Liu Y et al, *Clin Pharm Ther* 2017). Our laboratory has a heavy reliance on computational approaches, as we use genome-wide tools to interrogate genetic variability.
We also use chemical analyses (e.g. HPLC, LC/MS) to study medication pharmacokinetics, cell culture models, molecular biologic techniques, murine models, and analysis of clinical outcomes and phenotypes.

In addition to discovery research, we lead work to implement preemptive clinical pharmacogenomic testing. This is accomplished locally at St. Jude via a clinical protocol, PG4KDS (www.stjude.org/pg4kds) and internationally via the Clinical Pharmacogenetics Implementation Consortium (CPIC®, www.cpicpgx.org) (Caudle et al *Genet Med* 2017). Our staff help lead efforts to

Figure 5. Manhattan plots of inverse log p values for associations of germline SNPvariants with risk of osteonecrosis in patients with ALL and in adults without ALL (top panel, Karol et al 2015) and in patients younger than 10 years of age (bottom panel, Karol et al, 2016). Variants in glutamate receptor genes were associated with osteonecrosis in all cohorts.

create and curate gene/drug pair CPIC prescribing guidelines. We collaborate with many investigators within the department, throughout St. Jude, within the COG, and within the Pharmacogenomics Research Network (PGRN).

Erin G. Schuetz, PhD

I joined the St. Jude Pharmaceutical Department in 1993. My lab studies cytochromes P450 (CYP) and other enzymes that metabolize many of the drugs administered to St. Jude patients. The lab identifies genetic determinants explaining variation in hepatic and intestinal CYP and AOX activities and, hence, variation in drug efficacy, toxicity and, ultimately, therapeutic outcome. The lab strategically uses both the candidate gene approach and exploits network and pathway analysis tools to illuminate the genetic variation in novel candidate genes affecting the CYP genetic network. The liver system biology/network approach has identified the node genes that, when individually perturbed, co-regulate many genes in the CYP network. My lab then uses deep resequencing of these novel candidate genes, and allelic expression imbalance analysis, to identify the functional and regulatory variants responsible for altering CYP activity and driving changes in the CYP expression network. Standard molecular, cellular and biochemical studies are then used to determine the functional consequence of

these variants. Retrospective association studies are performed to determine if functional variants in candidate genes translate to clinical differences in CYP mediated drug clearance.

Most recently our studies have focused on studying the impact of Vitamin D3 (VD3) sufficiency versus insufficiency on survival and chemotherapeutic efficacy and toxicity in a mouse model of acute lymphoblastic leukemia with the BCR-ABL fusion gene. These studies were prompted by the fact that a significant percentage of the pediatric population is VD3 deficient or insufficient, and that VD3 levels are further eroded during therapy because anti-chemotherapeutic regimens decrease the levels of the biologically active form of vitamin D3. Hence a major long-term consequence is a loss of bone mineral density in these pediatric patients during their peak bone building years. As a result, clinical trials have been initiated to determine whether vitamin D supplementation can correct VD3 insufficiency and improve bone density in children treated for leukemia. However, there was also a concern that vitamin D supplementation might cause drug interactions with medications metabolized by some drug metabolizing enzymes and drug transporters because the expression of some of them is regulated by VD3. Our results found that VD3 supplementation had no effect on the pharmacokinetics of glucocorticoids. However, because our results demonstrated a significant effect of VD3 on survival of mice from the BCR-ABL+ leukemia, and that the combination of VD3 and glucocorticoid therapy may prove beneficial in treating BCR-ABL+ leukemia, efforts are underway to determine the mechanisms by which VD3 mediates these effects.

John D. Schuetz, PhD

A member of the Pharmaceutical Department since December 1992, my laboratory focuses on understanding the contribution of ABC transporters to pathological processes and pharmacological response using cell culture model systems as well as gene knockout models (e.g., reviewed *Ann Rev Pharm Tox,* 2006 and 2013). Using these model systems, we have, through collaborative effort with other SJCRH investigators, identified one ABC transporter as an important stem cell marker (Zhou et al, *Nat Med,* 2001, Zhou et al, *PNAS*, 2002) that has a prominent role in hematopoietic cell survival under hypoxia (Krishnamurthy et al, *J Biol Chem*, 2004) as well as myeloid leukemia (Fukuda et al, *JCI Insight*, 2017). We extended these studies to establish a knockout mouse which revealed for the first time that the ABC transporter (ABCC4/Mrp4) was important in protecting the brain from penetration of chemotherapeutic agents (Leggas et al, *Mol Cell Biol*, 2004). One could infer from these findings that the therapeutic efficacy of CNS-directed drugs that are Mrp4 substrates may be improved by developing Mrp4 inhibitors. The ABCC4/Mrp4 transporter was first functionally defined by my laboratory (Schuetz et al, *Nat Med*, 1999) and was demonstrated to protect hematopoietic cells from injury due to the widely used immunosuppressive and cancer chemotherapeutic agent 6-mercaptopurine. This finding allowed us through collaborative efforts within the department (Evans, Relling, E. Schuetz) to identify a defective ABCC4 allele that was prevalent in the Asian population, thus providing an explanation for the anecdotal reports of enhanced sensitivity to the toxic hematopoietic side-effects of 6 mercaptopurine in this population (*Krishnamurthy* et al, *Cancer Res,* 2008). Further studies suggest ABCC4 has a strong role in CFTR (Li, et al, *Cell*, 2007) and also in modulating platelet aggregation as well as response to anti-platelet drugs (Cheepala, Pitre, et al, *Blood* 2015). Other studies have focused on a mitochondrial and plasma membrane ABC transporter we first characterized (Krishnamurthy et al, *Nature*, 2006; Fukuda et al, *J Biol Chem*, 2011) that protects cells from oxidative stress (Lynch et al, *Cancer Res,* 2009) and also is a key genetic modifier of porphyrin, a disease of disrupted heme synthesis (Fukuda et al, *Nat Comm*, 2016). Because over a third of ABC transporters contribute to disease processes, our goal has been to understand the role of these genes in pathological conditions, such as our recently described roles for

the bile acid transporter, *Abcb11,* in protecting against neonatal respiratory distress (Zhang et al, *Nat Comm, 2015*). From this perspective, we have also been elucidating how select ABC transporters contribute to cancer (medulloblastoma) (Morfouace et al, *Cancer Res.* 2105) and therapeutic response (Pitre et al, *Nat Comm*, 2017).

Clinton F. Stewart, PharmD

I joined the Pharmaceutical Department at St. Jude in 1991, and since then have focused my research efforts in developmental therapeutics for children with solid malignancies and central nervous system (CNS) tumors. In the clinic, my research involves the application of state of the art pharmacokinetic (individual and population), pharmacogenetic, and pharmacodynamic approaches to understanding the variability in drug disposition in children with cancer. Little is known about the disposition of anti-cancer agents in infants and young children less than 3 years of age, which often leads to increased risk of morbidity, poor tumor control, and increased incidence of late effects. Thus, we have embarked on a comprehensive series of pharmacokinetic, pharmacogenetic, and pharmacodynamic studies to understand how developmental changes in infants and young children affect the disposition and toxicities of anticancer drugs used in the treatment of infants with malignant brain tumors. Our long-term goal is to determine rational dosing regimens for infants and young children by better understanding the developmental pharmacology of anti-cancer drugs and to apply these regimens to therapy for other childhood malignancies and chronic medical conditions. In addition to these clinical studies we perform at St. Jude, my lab collaborates with investigators within the Pediatric Brain Tumor Consortium and the Children's Oncology Group.

Figure 6. Schematic overview of our approach to using pharmacokinetic modeling and simulation in the identification of new anticancer drugs for treatment of pediatric CNS tumors.

Our work in the laboratory is guided by addressing clinically relevant problems encountered in the therapy of children with brain tumors (e.g., CNS drug penetration in brain tumors). The studies in the lab are designed to either yield data that can be translated into the design of improved clinical trials or to answer questions generated in the clinic. For example, the treatment of children with primary CNS tumors continues to be a challenge despite recent advances in technology and diagnostics. A variety of issues unique to pediatric CNS tumors impede development and clinical success of novel therapies, and for this reason, safe and effective treatments remain elusive. The preclinical approach we use (Figure 6) employs tumor subgroup-specific models of pediatric CNS tumors, cerebral microdialysis

sampling of tumor extracellular fluid (tECF), and pharmacokinetic modeling and simulation to overcome challenges that currently hinder researchers in this field.

Jun J. Yang, PhD

I joined the St. Jude faculty in 2010 and I am currently an Associate Member in the Pharmaceutical Department. The research focus of my group is pharmacogenomics of treatment outcomes (e.g. relapse) and toxicity in children with childhood acute lymphoblastic leukemia (ALL). Primarily taking a genome-wide approach, we identify genetic variations that contribute to interpatient variability in response to ALL therapy. By doing so, the goals of our research are to elucidate biological pathways dictating response to antileukemic drugs, to identify genetic predictors for drug resistance which can be utilized for treatment individualization, and to develop novel therapeutic agents to overcome drug resistance. Because genetic factors in both host and tumor genome can affect drug response, my lab has focused on characterization of inherited (germline) and acquired (somatic) genetic factors that are associated with treatment response in childhood ALL. We have led the first genome-wide association study to identify germline genetic variations associated with minimal residual disease in response to remission induction therapy in children with ALL (Yang et al, *JAMA,* 2009) and the first genome-wide interrogation of copy number alterations related to ALL relapse (Yang et al, *Blood,* 2008). We are particularly interested in the genetic basis for racial/ethnic differences in ALL treatment outcomes and disease susceptibility, e.g. we performed genome-wide studies to characterize ancestry-related genetic variants (Perez-Andreu et al, *Nat Genet* 2013, *J Clin Oncol* 2012, *J Natl Cancer Inst* 2013) that contribute to higher risk of relapse in Hispanic children with ALL (Yang et al, *Nat Genet*, 2011). We are also interested in pharmacogenetics of treatment toxicity, especially thiopurine-related myelosuppression (J Clin Oncol 2015, Nat Genet 2016). Our group is part of the NIH Pharmacogenomics Research Network (PGRN) and the Center for Precision Medicine for Leukemia (CPML).

Daniel Savic, PhD

I joined the Pharmaceutical Department at St. Jude Children's Research Hospital in August of 2016. Prior to my faculty appointment at St. Jude, I was a member of the Encyclopedia of DNA Elements (ENCODE) consortium, a large, multi-center, collaborative effort that aims to functionally annotate the human genome. To better understand genome structure and function, I applied a variety of functional genomic techniques and next-generation reporter assays (Savic et al. *Genome Research* 2015, Savic et al. *Genome Medicine* 2016, review in Engel et al. *Semin Cell Dev Biol* 2016, Ramaker and Savic et al. *Genome Research* 2017), and further engineered novel ChIP-seq based technologies that expand the utility (Savic et al. *Epigenetics and Chromatin* 2013) and enhance the capacity (Savic et al. *Genome Research* 2015) of the ChIP-seq functional genomic assay.

My laboratory at St. Jude focuses on the pharmacogenomics of treatment in pediatric acute lymphoblastic leukemia (ALL) in order to better understand the molecular underpinnings of anticancer drug resistance and disease relapse. Our group aims to address a fundamental and critical question in ALL pharmacogenomics: how does the noncoding regulatory genome impact antileukemic drug resistance and disease relapse? Our laboratory works on three interrelated projects that involve: (1) elucidating the role of noncoding, gene regulatory elements in antileukemic drug resistance, (2) functionally characterizing noncoding sequence variants at genomic loci associated with ALL treatment outcome, and (3) developing novel, high-throughput assays to

phenotypically screen noncoding sequences. We are also part of the Pharmacogenomics Research Network (PGRN), as well as the Center for Precision Medicine in Leukemia (CPML).

Liqin Zhu, PhD

I joined the Pharmaceutical Department as a Research Associate in 2016 and was promoted to an Assistant Member in 2017. My research program focuses on studying the molecular mechanisms driving the metastasis of pediatric hepatoblastoma (HB) and hepatocellular carcinoma (HCC) and identifying novel therapeutic targets for the aggressive forms of these diseases. We use three main approaches to study HB and HCC metastasis, including: (1) establish in vitro 3D organoid models for HB and HCC using tumors from genetic mouse models and human patients and discover novel biomarkers that are predictive of the diagnosis and prognosis of the parental tumors via comprehensive genomic profiling of the organoids; (2) use gene-orientated approaches to study the mechanisms driving liver cancer metastasis via organoid-driven orthotopic transplantation models of metastatic HB and HCC; (3) identify new treatment for metastatic HB and HCC via organoid-based drug testing using both targeted approaches developed from our mechanistic study and high-throughput drug screens. Our preliminary study has demonstrated the ability of HB and HCC organoids to drive highly invasive and metastatic tumors in vivo which faithfully recapitulated recurrent and metastatic tumors in patients at both histologic and molecular levels. Our transcriptomic study has identified a small number of genes that are significantly associated with the aggressiveness of HB and HCC tumors and organoids. We are currently testing the biological functions and therapeutic values of these candidate genes in our models with a long-term goal to develop new therapies for high risk liver cancers that are otherwise refractory to standard-of-care treatments.

Pharmaceutical Services

Pharmaceutical Services is led by Dr. William Greene and is staffed by pharmacists, pharmacy technicians, research and administrative staff, and faculty, (see Organization Chart at end) all dedicated to helping patients. St. Jude Pharmaceutical Services focuses on providing the best pharmaceutical care required for each child at SJCRH while supporting a collective research endeavor. Our personnel, working with other caregivers in a cutting-edge collaborative environment assure the best possible outcomes of drug therapy. Nearly 140 pharmacists, technicians, and other support personnel are involved in the care of patients and support of clinical research at St. Jude, helping to fulfill our organizational mission to "advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment."

Pharmaceutical Services addresses St. Jude patients across the continuum of care – providing services while they are inpatients, in the outpatient clinic, and while in domiciliary facilities or at home. Inpatient services include Clinical Pharmacist collaboration in management of patients of all major clinical patient care groups, including Leukemia/Lymphoma, Solid Tumor, Neuro-Oncology, Bone Marrow Transplant, Hematology, and HIV services. After discharge from the hospital, these patients are seen in outpatient clinics located on campus where pharmacists are directly involved with provider teams. In these settings, clinical pharmacists collaborate in the care of these patients, including the ordering of medications and laboratory tests, the development of clinical treatment protocols, provision of drug therapy and nutritional support consults, and assessment and management of the long-term effects of medication therapy. An on-site infusion center pharmacy provides medications for outpatients, and is fully staffed by pharmacists. On average, there are

approximately 350 patient clinic visits per day, with 110 infusion center encounters, leading to the dispensing of over 700 prescriptions or doses per day.

An inpatient census of approximately 55 patients per day requires more than 2,100 dispensed doses per day. Nutrition support, pharmacokinetic, and pharmacogenetic consults, (Figure 7) and routine medication reconciliation at discharge require direct pharmacist involvement in patient care. Patients requiring intravenous therapy while outside the hospital are managed through provision of therapy by the St. Jude Home Infusion Pharmacy. This service, initiated in early spring of 2011, was recognized by a Joint Commission surveyor as exhibiting several "best practices" and having no recommendations for improvement during multiple TJC surveys. This service is now providing more than 340 doses per day, and is caring for all St. Jude patients in the immediate service region. At St. Jude, we provide the very best professional environment for pharmacists (Figure 8) – one that supports growth and achievement of professional goals. Clinical Staff Pharmacists work from both centralized and decentralized settings to collaborate with clinical providers in patient care. Clinical Research Pharmacists, Informatics Pharmacists, and pharmacist leaders in medication outcomes and medication safety work to assure optimal system support and design to facilitate the best outcomes of patient care and clinical research. Certified Pharmacy Technicians collaborate with pharmacists to assure excellence in operational functions. A technician career ladder has been developed, and pharmacist developmental pathways provide internal opportunities for professional growth.

Figure 7: Pharmacogenetic test results generated as part of PG4KDS protocol (DMET) are highly concordant with test results generated via whole exome sequencing (WES) and via whole genome sequencing (WGS) (Yang W et al, Clin Pharm Ther 2016)

Professional society involvement is encouraged, and resources are dedicated to enhance professional growth. St. Jude pharmacists play an active role in the Children's Oncology Group, American College of Clinical Pharmacy, American Society of Health-System Pharmacy, and many other professional organizations.

St. Jude Pharmaceutical Services also collaborates closely with various colleges of pharmacy in providing experiential education to pharmacy students. The department is formally affiliated with the University of Tennessee (UT) College of Pharmacy, but also works with students from other colleges as they request the opportunity. Members of the department hold affiliated faculty appointments with the UT College of Pharmacy. St. Jude pharmacy personnel provide over 50 student-months of "advanced experiential" training experience, additional "introductory" experiences, and approximately 40 contact hours of classroom training for pharmacy students from various colleges of pharmacy (primarily UT).

Figure 8. Pharmacists are integral members of each of St. Jude's clinical services.

Pharmacists are integrated into each of the major clinical services at St. Jude and state-of-the-art distribution and computer support systems assure efficient, effective delivery and use of medications. Pharmaceutical Services Informatics is intimately involved in the maintenance and refinement of a complete electronic medical record with computerized prescriber order entry and clinical decision support. These same personnel lead efforts to identify and implement the best technology to ensure optimal and safe patient outcomes.

Pharmacy Specialty Residencies

Trainees at St. Jude are supported by an institutional Office of Academic Programs, whose goal is to assist our investigators and professional staff to improve the quality of experiences, training, benefits, and support for our undergraduate, graduate, professional and postdoctoral trainees. Over 300 post-doctoral trainees (post-Ph.D, M.D, and Pharm.D.) are at St. Jude, among whom are our PGY2 pharmacy specialty residents. Our PGY2 residencies in Pediatric Oncology, Medication Use Safety, and Pharmacogenomics are accredited by the American Society of Health System Pharmacists (ASHP). Further details are available on St. Jude's website (www.stjude.org/pharmacyresidency).

Figure 9. St. Jude PGY2 residents 2017-2018 (left to right): Cameron Thomas, PharmD, Kelsey Hyman, PharmD, Arathi Lambrix, PharmD; Phil Carpiniello, PharmD,

Pharmacokinetics Shared Resource (PKSR):

The Pharmacokinetics Shared Resource is part of the NCI-designated Cancer Center, is housed within Pharmaceutical Sciences laboratory space, is directed by Dr. Mary Relling and Dr. Kristine Crews, and provides centralized high-quality, competitively funded, peer-reviewed pharmacokinetic/pharmacodynamics research in both clinical and pre-clinical models at the St. Jude

Cancer Center. Dr. Carl Panetta is the PKSR's biomedical modeler, who leads regular PK/PD workshops at St. Jude. There are four major functions of the PKSR:

1. **Assist investigators with implementation of clinical protocols involving PK/PD studies, including assisting with study design and optimal sampling**. Implementation includes set-up of Cerner mnemonics and instructions, set-up of laboratory procedures and tracking mechanisms, communication with sponsors and investigators, refinement of PK sampling, PK nursing assistance, in-servicing of clinical departments, development of standard physician orders, building computerized laboratory tests, refining sampling and study design (see function #4 below), and development of pharmacokinetic data collection forms.
2. **Ensure efficient and proper acquisition and initial processing of biological samples for clinical PK/PD research studies (centralized receiving, initial processing, storage, and distribution)**. Processing of clinical research samples includes computerized tracking and labeling systems for acquisition, tracking, and distribution; initial centrifugation; long- and short-term storage; and distribution to other investigators within St. Jude and outside of St. Jude.
3. **Analytical assay implementation, validation, and ongoing quality control.** Analytical assay implementation includes stringent validation procedures, the guidelines for which are available in the FDA's [Guidance for Industry: Bioanalytical Method Validation](). Ongoing and systematic analytical quality control procedures are in place for all PK Shared Resource assays. Equipment is interfaced with state-of-the-art laboratory information management systems and biomedical modeling software.
4. **Develop and apply novel biomedical modeling.** Dr. Panetta and the department faculty assist with biomedical modeling, which has three main phases: model design, sampling strategies, and data analysis. The model design phase involves determining the most appropriate pharmacokinetic/pharmacodynamic model which adequately describes the data, considering historical and preliminary clinical data. The sampling strategies phase involves determining the most appropriate sampling times (using D-optimality methods); those that provide the most pharmacokinetic/pharmacodynamic information with the least inconvenience to the patients and staff. The data analysis phase involves determining and using the most appropriate nonlinear curve fitting techniques to best describe the data. These include maximum likelihood estimation, maximum a posteriori probability (MAP) estimation for individual results, and linear and nonlinear mixed effects modeling methods for population results.

Clinical Pharmacokinetics Laboratory

The Clinical Pharmacokinetics Laboratory (CPK lab), located in the Pharmaceutical Department, supports St. Jude's mission by providing state of the art therapeutic drug monitoring and pharmacogenetic testing that is interpreted by clinical pharmacists to assure optimal drug dosing. It is directed by Dr. Alejandro Molinelli with translational support from Dr. Kristine Crews.

The Clinical Pharmacokinetics Laboratory is certified as a high complexity laboratory by CLIA and is accredited by the College of American Pathologists. Our staff consists of licensed medical laboratory scientists. Every year the laboratory will process and analyze approximately 10,000 clinical specimens and send-out another 300 to reference laboratories. The laboratory's in-house test menu includes multiple high-complexity assays ranging from therapeutic drug determinations (e.g. immunosuppressant, antifungal drugs) to glomerular filtration rate estimation using 99mTc- DTPA.

Some of our resources include random access immunochemistry analyzers (e.g. Abbott Architect) and analytical instrumentation (e.g. LC-MS/MS, GC/MS, HPLC).

Most of our instruments have bidirectional interfaces with the Cerner Millennium clinical informatics system. The laboratory also handles pharmacogenetic testing for the hospital, offering genotyping results that are always accompanied by consults prepared by the clinical pharmacists or residents.

The laboratory staff and pharmacists at St. Jude work closely to provide results in a timely manner. Once a test result is obtained, the laboratory scientists alert the pharmacist, who in turn prepares a clinical consult. This close integration of care assures that our patients receive the best treatment while minimizing adverse effects from the drugs. The laboratory staff is also involved in clinical translational science projects, for which tests developed in the research laboratories are validated and incorporated into the CPK lab test menu as needed.

In addition to the samples for clinical testing, the CPK laboratory staff members also process thousands of patient research specimens a year, in support of various St. Jude research protocols, for the Pharmacokinetics Shared Resource.

Pharmaceutical Department Publications
2016-2017

Agee JM, Varley KE, Gertz J, Savic D, Roberts BS, Bailey SK, Shevde LA, Ramaker R, Lasseigne BN, Kirby MK, Newberry K, Partridge EC, Oliver PG, Sexton KG, Grizzle WE, Forero A, Buchsbaum DJ, Myers RM Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget 8(5)8226-8238, 2017. PMCID: PMC5352396 PMID: 28030809

Aguero, D, Cooley T, De la Torre C, Ferer DS, Friudenberg P, Nickman NA, Ordway B, Tjhio D, Urbanski C, Volpe G, Wolfe A. Optimizing Automation and Technology across a Pharmacy Enterprise. American Journal of Health-System Pharmacy September 2016, 73 (17) 1347-1350 PMID: 27543579

Allen SJ, Zellmer WA, Knoer SJ, Phelps PK, Marvin KC, Pulvermacher A, Hoffman JM, Li E, Shane R, Tyler LS, Fox ER, Scheckelhoff DJ, Zellmer WA, Meyer BM. ASHP Foundation pharmacy forecast 2017: Strategic planning advice for pharmacy departments in hospitals and health systems. Am J Health Syst Pharm 74: (2)27-53, PMID: 27879232

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2)210-216. PMCID: 5760397 PMID: 29152729

Archer NP, Perez-Andreu V, Scheurer ME, Rabin KR, Peckham-Gregory EC, Plon SE, Zabriskie RC, De Alarcon PA, Fernandez KS, Najera CR, Yang JJ, Antillon-Klussmann F, Lupo PJ. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Cancer 122 (23)3697-3704, 2016. PMCID: PMC5115939 PMID: 27529658

Aziz A, Kawamoto K, Eilbeck K, Williams MS, Freimuth RR, Hoffman MA, Rasmussen LV, Overby CL, Shirts BH, Hoffman JM, Welch BM. The genomic CDS sandbox: An assessment among domain experts. J Biomed Inform 60:84-94, 2016. PMCID: PMC4948866 PMID: 26778834

Bainer RO, Trendowski MR, Cheng C, Pei D, Yang W, Paugh SW, Goss KH, Skol AD, Pavlidis P, Pui CH, Gilliam TC, Evans WE, Onel K. A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia. Cancer Manag Res 9:397-410, 2017. PMCID: PMC5602435 PMID: 28979163

Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19:1135-1144, 2017. PMCID: PMC5570236 PMID: 28339824

Bank P, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, Relling MV, Guchelaar HJ. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther 2017. PMCID: PMC5723247 PMID: 28994452 [Epub ahead of print]

Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JA, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 102(2):213-218, 2017. PMCID: PMC5479760 PMID: 28002639

Boswell-Casteel RC, Fukuda Y, Schuetz JD. ABCB6, an ABC Transporter Impacting Drug Response and Disease. APPS J. 2017; 20(1):8. PMID: 29192381

Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW. Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma. J Clin Oncol 35(1):72-77, 2017. PMCID: PMC5455691 PMID: 28034080

Burlison JD, Quillivan RR, Kath LM, Zhou Y, Courtney SC, Cheng C, Hoffman JM. A multilevel analysis of U.S. hospital patient safety culture relationships with perceptions of voluntary event reporting. J Patient Saf, 2016. [Epub ahead of print] PMCID: PMC5415419 PMID: 27820722

Burlison JD, Quillivan RR, Scott SD, Johnson S, Hoffman JM. The effects of the second victim phenomenon on work-related outcomes: Connecting self-reported caregiver distress to turnover intentions and absenteeism. J Patient Saf, 2016. PMCID: PMC5413437 PMID: 27811593

Burlison JD, Scott SD, Browne EK, Thompson SG, Hoffman JM. The Second Victim Experience and Support Tool: Validation of an organizational resource for assessing second victim effects and the quality of support resources. J Patient Saf 13:93-102, 2017. PMCID: PMC4342309 PMID: 25162208

Cao X, Crews KR, Downing J, Lamba J, Pounds SB. CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints. BMC Bioinformatics 17:382, 2016. PMCID: PMC5073973 PMID: 27766934

Cast A, Valanejad L, Wright M, Nguyen P, Gupta A, Zhu L, Shin S, Timchenko N. C/EBPa-dependent de-differentiation of hepatocytes into stem-like cells is an early step of development of liver cancer. Hepatology, 2017[Epub ahead of print] PMID:29159818

Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm 73(23):1977-1985, 2016. PMCID: PMC5117674 PMID: 27864205

Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 19(2):215-223, 2017. PMCID: PMC5253119 PMID: 27441996

Chhibber A, French CE, Yee SW, Gamazon ER, Theusch E, Qin X, Webb A, Papp AC, Wang A, Simmons CQ, Konkashbaev A, Chaudhry AS, Mitchel K, Stryke D, Ferrin TE, Weiss ST, Kroetz DL, Sadee W, Nickerson DA, Krauss RM, George AL, Schuetz EG, Medina MW, Cox NJ, Scherer SE, Giacomini KM, Brenner SE. Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines. Pharmacogenomics J 17(2):137-145, 2017. PMCID: PMC4980276 PMID: 26856248

Chow JW, Chicella MF, Christensen AM, Moneymaker CS, Harrington J, Dice JE. Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic. J Pediatr Pharmacol Ther 22(5):338-343, 2017. PMCID: PMC5640300 PMID: 29042834

Chilsolm DA, Savic D, Moore AJ, Ballesteros-Tato A, Leon B, Crossman DK, Murre C, Myers RM, Weinmann AS. CTCF translates IL-2- and αKG-sensitive metabolic changes in T cells into context-dependent differentiation gene programs. Immunity 47(2):251-267, 2017. PMCID: PMC5654635. PMID: 28813658

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF. Translational pharmacokinetic-pharmacodynamic modeling and simulation: Optimizing 5-fluorouracil dosing in children with pediatric ependymoma. CPT Pharmacometrics Syst Pharmacol 5(4):211-221, 2016. PMCID: PMC4834132 PMID: 27104090

Diouf B, Crews KR, Evans WE. Vincristine pharmacogenomics: 'winner's curse' or a different phenotype? Pharmacogenet Genomics 26:51-52, 2016. PMID: 26704670

Diouf B, Devaraju P, Janke LJ, Fan Y, Frase S, Eddins D, Peters JL, Kim J, Pei D, Cheng C, Zakharenko SS, Evans WE. Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion, and altered sensory function in mice. Sci Rep 6:30757-, 2016. PMCID: PMC4967871 PMID: 27476972

Diouf B, Lin W, Goktug A, Grace CRR, Waddell MB, Bao J, Shao Y, Heath RJ, Zheng JJ, Shelat AA, Relling MV, Chen T, Evans WE. Alteration of RNA splicing by small-molecule inhibitors of the interaction between NHP2L1 and U4. SLAS Discov 23(2):164-173 2017. PMCID: PMC5783296 PMID: 28985478

Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity B, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS, Jacobson PA, Israni AK. CRISPR/Cas9 genetic modification of CYP3A5 *3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism. Drug Metab Dispos 45(8):957-965, 2017. PMCID: PMC5518718 PMID: 28533324

Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 99(6):651-660, 2016. PMCID: PMC4898266 PMID: 26663398

Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol 77(6):1231-1243, 2016. PMCID: PMC4918815 PMID: 27125973

Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD. ABCC4 is a determinant of cytarabine-induced cytotoxicity and myelosuppression. Clin Transl Sci 9 (1):51-59, 2016. PMCID: PMC4905720 PMID: 26842729

Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR. Neurocognitive and patient-reported outcomes in adult survivors of childhood osteosarcoma. JAMA Oncol 2(2):201-208, 2016. PMCID: PMC4752424 PMID: 26583357

Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. *Cancer Chemother Pharmacol* 77(5):1039-1052, 2016. PMCID: PMC4846505 PMID: 27053087

Eissa HM, Zhou Y, Panetta JC, Browne EK, Jeha S, Cheng C, Relling MV, Campana D, Pui CH, Inaba H. The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. Blood Cancer J 7(2): e531 2017. PMCID: PMC5533940 PMID: 28212374

Ellis JL, Bove KE, Schuetz EG, Leino D, Valencia CA, Schuetz JD, Miethke A, Yin C. Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion impaired by bile salt export pump deficiency. Hepatology, 2017. [Epub ahead of print] PMID: 29091294

Engel KL, Mackiewicz M, Hardigan AA, Myers RM, Savic D. Decoding transcriptional enhancers: Evolution from annotation to functional interpretation. Semin Cell Dev Biol 57:40-50, 2016. PMCID: PMC5018832 PMID: 27224938

Flerlage T, Hayden R, Cross SJ, Dallas R, Srinivasan A, Tang L, Sun Y, Maron G. Rotavirus Infection in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients: Clinical Course and Experience Using Nitazoxanide and Enterally Administered Immunoglobulins. Pediatr Infect Dis J. 2017 37(2):176-181. PMID: 28787390

Freimuth RR, Formea CM, Hoffman JM, Matey E, Peterson JF, Boyce RD. Implementing genomic clinical decision support for drug-based precision medicine. CPT Pharmacometrics Syst Pharmacol 6(3):153-155, 2017. PMCID: PMC5351408 PMID: 28109071

Fukuda Y, Wang Y, Lian S, Lynch J, Nagai S, Fanshawe B, Kandilci A, Janke LJ, Neale G, Fan Y, Sorrentino BP, Roussel MF, Grosveld G, Schuetz JD. Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis. JCI Insight2017, 2(15) [Epub ahead of print] PMID: 28768907

Fukuda Y, Cheong PL, Lynch J, Brighton C, Frase S, Kargas V, Rampersaud E, Wang Y, Sankaran VG, Yu B, Ney PA, Weiss MJ, Vogel P, Bond PJ, Ford RC, Trent RJ, Schuetz JD. The severity of hereditary porphyria is modulated by the porphyrin exporter and Lan antigen ABCB6. Nat Commun 7:12353-, 2016. PMCID: PMC4987512 PMID: 27507172

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics 138(1) 2016. PMCID: PMC4925073 PMID: 27335380

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel S, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther 99(4):363-369, 2016. PMCID: PMC4785051 PMID: 26417955

Haidar CE, Hoffman JM, Gammal RS, Relling MV, Crews KR. Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. Am J Health Syst Pharm2017 74(6):409-415. PMID: 28274984

Hardy KK, Embry LM, Kairalla JA, Helian S, Devidas M, Armstrong FD, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, Winick N. Reply to I.J. Cohen. J Clin Oncol: JCO 2017, 35(35) 3989-3991PMID: 29045162

Hardy KK, Embry L, Kairalla JA, Helian S, Devidas M, Armstrong D, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, Winick N. Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies: A report from the Children's Oncology Group. J Clin Oncol 2017 35(23):2700-2707. PMCID: PMC5549456 PMID: 28671857

Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm 73(23):1967-1976, 2016. PMCID: PMC5117634 PMID: 27864204

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102:37-44, 2017. PMCID: PMC5478479 PMID: 27997040

Hoffman JM, Dunnenberger HM, Kevin Hicks J, Caudle KE, Whirl Carrillo M, Freimuth RR, Williams MS, Klein TE, Peterson JF. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). J Am Med Inform Assoc 23(4):796-801, 2016. PMID: 27026620

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist 21(12):1471-1482, 2016. PMCID: PMC5153332 PMID: 27496039

Hungate EA, Vora SR, Gamazon ER, Moriyama T, Best T, Hulur I, Lee Y, Evans TJ, Ellinghaus E, Stanulla M, Rudant J, Orsi L, Clavel J, Milne E, Scott RJ, Pui CH, Cox NJ, Loh ML, Yang JJ, Skol AD, Onel

K. A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat Commun 7:10635-, 2016. PMCID: PMC4754340 PMID: 26868379

Hu S, Qian M, Zhang H, Guo Y, Yang J, Zhao X, He H, Lu J, Pan J, Chang M, Du G, Lin TN, Kham SK, Quah TC, Ariffin H, Tan AM, Cheng Y, Li C, Yeoh AE, Pui CH, Skanderup AJ, Yang JJ. Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations. Blood 129(24):3264-3268, 2017. PMCID: PMC5472902 PMID: 28408461

Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, Varechtchouk O, Hahn T, Buaboonnam J, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Cheng C, Evans WE, Relling MV, Pui CH. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol 28(2):386-392, 2017. PMID: 28426102

Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: Update of the literature. Clin Pharmacokinet 55(3):297-311, 2016. PMCID: PMC4761278 PMID: 26293618

Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, and Cavallari LH, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin Pharmacol Ther* 102(3):397-404, 2017. PMCID: PMC5546947 PMID: 28198005

Kala A, Patel YT, Davis A, Stewart CF. Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study. J Chromatogr B Analyt Technol Biomed Life Sci 1057:110-117, 2017. PMCID: PMC5512115 PMID: 28521250

Kalman LV, Agundez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Tredici AD, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Muller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 99(2):172-185, 2016. PMCID: PMC4724253 PMID: 26479518

Kanamitsu K, Kusuhara H, Schuetz JD, Takeuchi K, Sugiyama Y. Investigation of the importance of multidrug resistance-associated protein 4 (Mrp4/Abcc4) in the active efflux of anionic drugs across the blood-brain barrier. J Pharm Sci 106(9):2566-2575, 2017. PMID: 28456721

Karol SE, Mattano LA Jr, Yang W, Maloney KW, Smith C, Liu C, Ramsey LB, Fernandez CA, Chang TY, Neale G, Cheng C, Mardis E, Fulton R, Scheet P, San Lucas FA, Larsen EC, Loh ML, Raetz EA, Hunger SP, Devidas M, Relling MV. Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 127(5):558-564, 2016. PMCID: PMC4742546 PMID: 26590194

Karol SE, Larsen E, Cheng C, Cao X, Yang W, Ramsey LB, Fernandez CA, McCorkle JR, Paugh SW, Autry RJ, Lopez-Lopez E, Diouf B, Jeha S, Pui CH, Raetz EA, Winick NJ, Carroll WL, Hunger SP, Loh ML, Devidas M, Evans WE, Yang JJ, Relling MV. Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia 31(6):1325-1332, 2017. PMCID: PMC5462853 PMID: 28096535

Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. *Cancer* 123(18):3602-3608, 2017. PMCID: PMC5589497 PMID: 28493546

Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2017 [Epub ahead of print]

Kim MJ, Yu CY, Theusch E, Naidoo D, Stevens K, Kuang YL, Schuetz E, Chaudhry AS, Medina MW. SUGP1 is a novel regulator of cholesterol metabolism. Hum Mol Genet, 2016 25(14):3106-3116, PMCID: PMC5181593 PMID: 27206982

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE. Clinical significance of in vivo cytarabine-induced gene expression signature in AML. Leuk Lymphoma 57(4):909-920, 2016. PMCID: PMC4794368 PMID: 26366682

Landier W, Chen Y, Hageman L, Kim H, Bostrom BC, Casillas JN, Dickens DS, Evans WE, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Relling MV, Wong FL, Bhatia S. Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood 129(14):1919-1926, 2017. PMCID: PMC5383868 PMID: 28153823

Landier W, Hageman L, Chen Y, Kornegay N, Evans WE, Bostrom BC, Casillas J, Dickens DS, Angiolillo AL, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Relling MV, Wong FL, Bhatia S. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: A report from the Children's Oncology Group study AALL03N1. J Clin Oncol 35(15):1730-1736, 2017. PMCID: PMC5455766 PMID: 28339328

Lee SHR, Yang JJ. Pharmacogenomics in acute lymphoblastic leukemia. Best Pract Res Clin Haematol 30(3):229-236, 2017. PMID: 29050696

Leong R, Zhao H, Reaman G, Liu Q, Wang Y, Stewart CF, Burckart G. Bridging adult experience to pediatrics in oncology drug development. J Clin Pharmacol 57: S129-S135, 2017. PMID: 28921643

Li L, Qian M, Chen IH, Finkelstein D, Onar-Thomas A, Johnson M, Calabrese C, Bahrami A, López-Terrada DH, Yang JJ, Tao WA, *Zhu L*. Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice. Am J Pathol 2017 (17)30865-9 [Epub ahead of print]

Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, Winick NJ, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J,

Mullighan CG. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 49(8):1211-1218, 2017. PMCID: PMC5535770 PMID: 28671688

Liu Y, Fernandez CA, Smith C, Yang W, Cheng C, Panetta JC, Kornegay N, Liu C, Ramsey LB, Karol SE, Janke LJ, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Yang JJ, Mullighan CG, Zhang J, Evans WE, Jeha S, Pui CH, Relling MV. Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. Clin Pharmacol Ther 102:131-140, 2017. PMCID: PMC5511775 PMID: 28090653

Liu C, Janke LJ, Yang JJ, Evans WE, Schuetz JD, Relling MV. Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. Cancer Chemother Pharmacol 80(2):287-293, 2017. PMCID: PMC5628515 PMID: 28623449

Liu C, Janke LJ, Kawedia JD, Ramsey LB, Cai X, Mattano LA Jr, Boyd KL, Funk AJ, Relling MV. Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. PLoS One 11(3):e0151433-, 2016. PMCID: PMC4788417 PMID: 26967741

Liu C, Yang W, Devidas M, Cheng C, Pei D, Smith C, Carroll WL, Raetz EA, Bowman WP, Larsen EC, Maloney KW, Martin PL, Mattano LA Jr, Winick NJ, Mardis ER, Fulton RS, Bhojwani D, Howard SC, Jeha S, Pui CH, Hunger SP, Evans WE, Loh ML, Relling MV. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J Clin Oncol 34(18):2133-2140, 2016. PMCID: PMC4962704 PMID: 27114598

Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, Hageman L, Chen Y, Yang JJ, Crews KR, Kornegay N, Karol SE, Wong FL, Jeha S, Sandlund JT, Ribeiro RC, Rubnitz JE, Metzger ML, Pui CH, Evans WE, Bhatia S, Relling MV. Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait. Clin Pharmacol Ther 101(3):373-381, 2017. PMCID: PMC5309133 PMID: 27564568

Liu YF, Wang BY, Zhang WN, Huang JY, Li BS, Zhang M, Jiang L, Li JF, Wang MJ, Dai YJ, Zhang ZG, Wang Q, Kong J, Chen B, Zhu YM, Weng XQ, Shen ZX, Li JM, Wang J, Yan XJ, Li Y, Liang YM, Liu L, Chen XQ, Zhang WG, Yan JS, Hu JD, Shen SH, Chen J, Gu LJ, Pei D, Li Y, Wu G, Zhou X, Ren RB, Cheng C, Yang JJ, Wang KK, Wang SY, Zhang J, Mi JQ, Pui CH, Tang JY, Chen Z, Chen SJ. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 8:173-183, 2016. PMCID: PMC4919728 PMID: 27428428

Liu Y, Fernandez CA, Relling MV. Response to "PNPLA3 rs738409 and hepatotoxicity in children with B-cell acute lymphoblastic leukemia: A validation study in a Spanish cohort". Clin Pharmacol Ther: 2017, 102(6). 907 PMID: 28744849

Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharmacol Ther 102(3):502-510, 2017. PMCID: PMC5511786 PMID: 28090649

McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson J, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. J Am Med Inform Assoc 23: e138-e141, 2016. PMCID: PMC4954613 PMID: 26499101

McDonough SL, Alford EL. Finks SW, Parker RB, Chisholm-Burns MA, and Phelps SJ. Student Pharmacists' Perceptions of a Composite Examination in Their First Professional Year. Am J Pharm Educ. 2016 Feb 25;80(1):4. PMCID: PMC4776297 PMID: 26941430

Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol 32:1575-1584, 2017. PMCID: PMC5712286 PMID: 28573537

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol 80(5):1013-1026, 2017. PMID: 28988277

Molinelli AR, Rose CH 4th. Quantification of the triazole antifungal compounds voriconazole and posaconazole in human serum or plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS/MS). Methods Mol Biol. 1383:39-47, 2016. PMID: 26660172.

Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol 126(2):225-234, 2016. PMCID: PMC4718940 PMID: 26518542

Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, Hofmann U, Komada Y, Kato M, McCorkle R, Li L, Koh K, Najera CR, Kham SK, Isobe T, Chen Z, Chiew EK, Bhojwani D, Jeffries C, Lu Y, Schwab M, Inaba H, Pui CH, Relling MV, Manabe A, Hori H, Schmiegelow K, Yeoh AE, Evans WE, Yang JJ. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 48(4):367-373, 2016. PMCID: PMC5029084 PMID: 26878724

Moriyama T, Yang YL, Nishii R, Ariffin H, Liu C, Lin TN, Yang W, Lin DT, Yu CH, Kham S, Pui CH, Evans WE, Jeha S, Relling MV, Yeoh AE, Yang JJ. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood 130(10):1209-1212, 2017. PMCID: PMC5606007 PMID: 28659275

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther 102:45-51, 2017. PMCID: PMC5474211 PMID: 27981572

Moriyama T, Nishii R, Lin TN, Kihira K, Toyoda H, Jacob N, Kato M, Koh K, Inaba H, Manabe A, Schmiegelow K, Yang JJ, Hori H. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 27(6):236-239, 2017. PMID: 28445187

Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI. Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo. Eur J Cancer 83:132-141, 2017. PMCID: PMC5665171 PMID: 28735070

Nakanishi T, Ohno Y, Aotani R, Maruyama S, Shimada H, Kamo S, Oshima H, Oshima M, Schuetz JD, Tamai I. A novel role for OATP2A1/SLCO2A1 in a murine model of colon cancer. Sci Rep. 2017; 7(1):16567. PMCID: PMC5707394 PMID: 29185482

Nakka P, Archer NP, Xu H, Lupo PJ, Raphael BJ, Yang JJ, Ramachandran S. Novel gene and network associations found for acute lymphoblastic leukemia using case-control and family-based studies in multiethnic populations. Cancer Epidemiol Biomarkers Prev 26(10):1531-1539, 2017. PMCID: PMC5626662 PMID: 28751478

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int J Cancer 141(7):1469-1477, 2017. PMID: 28631382

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A. Feasibility of pegylated interferon in children and young adults with resected high-risk melanoma. Pediatr Blood Cancer 63(7):1207-1213, 2016. PMCID: PMC4877209 PMID: 27038395

Nottage KA, Hankins JS, Faughnan LG, James DM, Richardson J, Christensen R, Kang G, Smeltzer M, Cancio MI, Wang WC, Anghelescu DL. Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study. *Clin Trials* 13(4):409-416, 2016. PMID: 27000103

Park HW, Tse S, Yang W, Kelly HW, Kaste SC, Pui CH, Relling MV, Tantisira KG. A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment. Pharmacogenomics J 17(2):180-185, 2017. PMCID: PMC4980282 PMID: 26856247

Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur AH, Hankins J, Relling MV, Haidar CE. The impact of the UGT1A1*60 allele on bilirubin serum concentrations. Pharmacogenomics 18(1):5-16, 2017. PMID: 27967321

Patel YT, Jacus MO, Davis AD, Boulos N, Turner DC, Vuppala PK, Freeman BB 3rd, Gilbertson RJ, Stewart CF. Simvastatin hydroxy acid fails to attain sufficient central nervous system tumor exposure to achieve a cytotoxic effect: Results of a preclinical cerebral microdialysis study. Drug Metab Dispos 44(4):591-594, 2016. PMCID: PMC4810761 PMID: 26802130

Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF. Population pharmacokinetics of selumetinib and its metabolite N-desmethyl-selumetinib in adult patients with advanced solid tumors and children with low-grade gliomas. CPT Pharmacometrics Syst Pharmacol 6(5):305-314, 2017. PMCID: PMC5445231 PMID: 28326681

Paugh SW, Coss DR, Bao J, Laudermilk LT, Grace CR, Ferreira AM, Waddell MB, Ridout G, Naeve D, Leuze M, LoCascio PF, Panetta JC, Wilkinson MR, Pui CH, Naeve CW, Uberbacher EC, Bonten EJ, Evans WE. MicroRNAs form triplexes with double stranded DNA at sequence-specific binding sites; a eukaryotic mechanism via which microRNAs could directly alter gene expression. PLoS Comput Biol 12(2):e1004744-, 2016. PMCID: PMC4742280 PMID: 26844769

Paugh SW, Bonten EJ, Evans WE. Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. Mol Cell Oncol 3(1): e1065947-, 2016. PMCID: PMC4845245 PMID: 27308575

Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19(8):1135-1144, 2017. PMCID: PMC5570236 PMID: 28339824

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, Gilbertson RJ. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 29(4):508-522, 2016. PMCID: PMC4829447 PMID: 27050100

Pitre A, Ge Y, Lin W, Wang Y, Fukuda Y, Temirov J, Phillips AH, Peters JL, Fan Y, Ma J, Nourse A, Sinha C, Lin H, Kriwacki R, Downing JR, Gruber TA, Centonze VE, Naren AP, Chen T, Schuetz JD. An unexpected protein interaction promotes drug resistance in leukemia. Nat Commun 8(1):1547-, 2017. PMCID: PMC5691054 PMID: 29146910

Portera MV, Karol SE, Smith C, Yang W, Cheng C, Neel MD, Pui CH, Relling MV, Kaste SC. Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer, 2017, 64(7). PMCID: PMC5596390 PMID: 28035753

Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 17:464-470, 2017. PMCID: PMC5638138 PMID: 28842136

Quillivan RR, Burlison JD, Browne EK, Scott SD, Hoffman JM. Patient safety culture and the second victim phenomenon: Connecting culture to staff distress in nurses. Jt Comm J Qual Patient Saf 42(8):377-386, 2016. PMCID: PMC5333492 PMID: 27456420

Ramaker RC*, Savic D*, Hardigan AA, Newberry K, Cooper GM, Myers RM, Cooper SJ. A genome-wide interactome of DNA-associated proteins in the human liver. Genome Res 27(11):1950-1960, 2017. PMCID: PMC 5668951 PMID: 29021291

Ramsey LB, Pounds S, Cheng C, Cao X, Yang W, Smith C, Karol SE, Liu C, Panetta JC, Inaba H, Rubnitz JE, Metzger ML, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Evans WE, Relling MV. Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics 27(8):294-302, 2017.PMCID: PMC5523978 PMID: 28628558

Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 2017 23(1):52-61 PMCID: PMC5759822 PMID: 29079637

Rau RE, Carroll AJ, Heerema NA, Arland L, Carroll WL, Winick NJ, Raetz EA, Loh ML, Yang W, Relling MV, Dai Y, Devidas M, Hunger SP. Klinefelter syndrome and 47, XYY syndrome in children with B cell acute lymphoblastic leukaemia. Br J Haematol 2017 179(5):843-846 PMCID: PMC5247399 PMID: 27434379

Relling MV, Krauss RM, Roden DM, Klein TE, Fowler DM, Terada N, Lin L, Riel-Mehan M, Do TP, Kubo M, Yee SW, Johnson GT, Giacomini KM. New pharmacogenomics research network: An open community catalyzing research and translation in precision medicine. Clin Pharmacol Ther: 2017. 102(6):897-902 PMCID: PMC5706548 PMID: 28795399

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF. Population pharmacokinetics of oral topotecan in infants and very young children with brain tumors demonstrates a role of ABCG2 rs4148157 on the absorption rate constant. Drug Metab Dispos 44(7):1116-1122, 2016. PMCID: PMC4931885 PMID: 27052877

Roederer MW, Kuo GM, Kisor DF, Frye RF, Hoffman JM, Jenkins J, Weitzel KW. Pharmacogenomics competencies in pharmacy practice: A blueprint for change. J Am Pharm Assoc (2003) 57(1):120-125, 2017. PMCID: PMC5373920 PMID: 27816542

Rybak JM, Dickens CM, Parker JE, Caudle K, Manigaba K, Whaley SG, Nishimoto A, Luna-Tapia A, Roy S, Zhang Q, Barker KS, Palmer GE, Sutter TR, Homayouni R, Wiederhold NP, Kelly SL, Rogers PD. Loss of C-5 sterol desaturase activity results in increased resistance to azole and echinocandin antifungals in a clinical isolate of Candida parapsilosis. Antimicrob Agents Chemother 2017 61(9) PMCID: PMC5571332 PMID: 28630186

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther 99(1):36-37, 2016. PMCID: PMC4675696 PMID: 26094938

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol 129(3):443-451, 2016. PMCID: PMC5288808 PMID: 27350411

Savic D, Ramaker RC, Roberts BS, Burwell TC, Dean EC, Meadows SK, Cooper SJ, Garabedian MJ, Gertz J, Myers RM. Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation. Genome Med 8(1):74, 2016. PMCID: PMC4940857 PMID: 27401066

Scott JR, Crews KR. Reply to: Glucarpidase for the treatment of methotrexate-induced renal dysfunction and delayed methotrexate excretion. Pediatr Blood Cancer 2016 63(2):365 PMID: 26488798

Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450

oxidoreductase content. Pharmacogenomics J 16(4):375-387, 2016. PMCID: PMC4775436 PMID: 26323597

Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nat Commun 2016 7:10880 PMCID: PMC4799362 PMID: 26979622

Stewart CF, Robinson GW. Development of molecularly targeted therapies to treat pediatric malignancies. Clin Pharmacol Ther 102(5):752-753, 2017. PMCID: PMC5656826 PMID: 28836264

Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WE. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 101(3):391-395, 2017. PMCID: PMC5320866 PMID: 27618250

Tanner JA, Prasad B, Claw KG, Stapleton P, Chaudhry A, Schuetz EG, Thummel KE, Tyndale RF. Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: Influence of genetic and nongenetic factors. J Pharmacol Exp Ther 360(1):129-139, 2017. PMCID: PMC5193072 PMID: 27815364

Thomson MM, Hines RN, Schuetz EG, Meibohm B. Expression patterns of organic anion transporting polypeptides 1B1 and 1B3 protein in human pediatric liver. Drug Metab Dispos 44(7):999-1004, 2016. PMCID: PMC4931892 PMID: 27098745

Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, Tien YC, Jeong H, Pan X, Shireman LM, Tay-Sontheimer J, Lin YS. Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab Dispos 44(3):343-351, 2016. PMCID: PMC4767386 PMID: 26681736

Varatharajan S, Panetta JC, Abraham A, Karathedath S, Mohanan E, Lakshmi KM, Arthur N, Srivastava VM, Nemani S, George B, Srivastava A, Mathews V, Balasubramanian P. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemother Pharmacol 78(5):1051-1058, 2016. PMD: 27738808

Walsh TJ, Moriyama B, Penzak SR, Klein TE, Caudle KE. Response to impact of CYP3A4 genotype on voriconazole exposure - New insights into the contribution of CYP3A4*22 to metabolism of voriconazole. Clin Pharmacol Ther 2017 103 (2):187 PMID: 28786218

Watts CS, Sciasci JN, Pauley JL, Panetta JC, Pei D, Cheng C, Christensen CM, Mikkelsen TS, Pui CH, Jeha S, Relling MV. Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. J Pediatr Hematol Oncol 38(6):449-452, 2016. PMCID: PMC4955728 PMID: 27322715

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a Children's Oncology Group Study ACNS1021. Cancer Med 5(7):1416-1424, 2016. PMCID: PMC4944867 PMID: 27109549

Wijaya J, Fukuda Y, Schuetz JD. Obstacles to Brain Tumor Therapy: Key ABC Transporters. Int J Mol Sci. 2017; 18(12). PMCID: PMC5751147 PMID: 29186899

Wolf J, Sun Y, Tang L, Newland JG, Gerber JS, Van Dyke CJ, Hymes SR, Yu D, Carias DC, Bryant PA. Antimicrobial stewardship barriers and goals in pediatric oncology and bone marrow transplantation: A survey of antimicrobial stewardship practitioners. Infect Control Hosp Epidemiol 37(3):343-347, 2016. PMID: 26639441

Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, Schuetz E, Rettie AE, Leeder JS, Thummel KE, Prasad B. Genetic and nongenetic factors associated with protein abundance of flavin-containing monooxygenase 3 in human liver. J Pharmacol Exp Ther 363(2):265-274, 2017. PMCID: PMC 5697103 PMID: 28819071

Yang W, Wu G, Broeckel U, Smith CA, Turner V, Haidar CE, Wang S, Carter R, Karol SE, Neale G, Crews KR, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV. Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clin Pharmacol Ther 100(4):380-388, 2016. PMCID: PMC5684873 PMID: 27311679

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrozek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 48(12):1481-1489, 2016. PMCID: PMC5144107 PMID: 27776115

Zhu L, Finkelstein D, Gao C, Shi L, Wang Y, Lopez-Terrada D, Wang K, Utley S, Pounds S, Neale G, Ellison D, Onar-Thomas A, Gilbertson RJ. Multi-organ mapping of cancer risk. Cell 166(5):1132-1146.e7, 2016. PMCID: PMC5067024 PMID: 27565343

Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD. Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Cancer Res 76(1):117-126, 2016. PMCID: PMC4713045 PMID: 26677977

ST. JUDE CHILDREN'S RESEARCH HOSPITAL - Pharmaceutical Department

Pharmaceutical Sciences

Mary V. Relling, PharmD
CHAIR

Pharmaceutical Services

John Schuetz, PhD
Vice-Chair

William Greene, PharmD, BCPS, FASHP
Chief Pharmaceutical Officer

Administrative Staff - Sciences
Jacquline Wicks-Callahan, MSOM, MBA
Administrative Director
Dawn Bowen, Coord-Pharm. Sci. Admin.
Loretta McDowell, Admin Spec
April Blankenship, Admin Spec
Andrea Westmoreland, Admin Spec

Administrative Staff - Services
Camille Doty, Admin. Manager (Services)
Taneshia Buckner-Briggs, Admin Spec
Astrid Mathis, Pharmacy Billing Coordinator
Laura Todd, Pharmacy Billing Coordinator
Amanda Ayers, Administrative Assistant II

Faculty
William Evans, PharmD
William Greene, PharmD
James Hoffman, PharmD
Mary Relling, PharmD
Daniel Savic, PhD
Erin Schuetz, PhD
John Schuetz, PhD
Clinton Stewart, PharmD
Jun J. Yang, PhD
Liqin Zhu, PhD

Clinical Research Nurses
Sheri Ring - Manager
Paula Condy, Margaret Edwards,
Shannon Gibbs, Terri Kuehner,
Melinda Wood

PK Shared Resources
Kris Crews, PharmD, Lab Director
Claire Mills, Coord PK
L. Li, PhD
Carl Panetta, Biomed Mod/
Pharmacometrician

Medication Outcomes & Safety
James Hoffman, Chief Patient Safety Officer
Jennifer Robertson, Medication Outcomes & Safety Officer
Jon Burlison, Patient Safety Research Associate
Delia Carias, Pharmacist, Clin Med Use Policy
Clay Daniels, PharmD, Clin Pharmacist

William Humphrey, Director, Pharmacy Operations
John McCormick, Director, Clinical Pharmacy Services
Steve Pate, Director, Outpatient Pharmaceutical Services
David Aguero, Manager, Medication Services & Informatics
Wendell Cheatham, Manager, Purchasing & Inventory
Barry Williams, Manager, Inpatient Services
Jennifer Pauley, Clinical Pharmacy Coord/Residency Program Director

Postdoctoral Fellows
J. Beard
R. Boswell-Casteel
C. Coke
R. Crawford
J. Diedrich
D. Ferguson
E. Finch
Y. Gocho
C. Goodings - Harris
T. Gose
L. Hamel
Z. Jones
Y. Li
Y. Liu
A. Maharaj
T. Moriyama
M. Qian
J. Wijaya
H. Zhang
Y. Zhang

Laboratory Staff
N. Atkinson
E. Bonten
O. Campagne
A. Chaudhry
Y. Chu
M. Chung
A. Davis
X. DeMeter
B. Diouf
G. Du
Y. Fukuda
H. Houke
J. Hunt
D. Jenkins
A. John
A. Kala
S. Kushwaha
L. Li
T. Lin
J. Lu
J. Lynch
P. McGill
K. Mukherjee
R. Nishii
T. Owens
M. Payton
N. Selvo
C. Suggs
C. Suiter
A. Vasilyeva
Yan Wang
Yao Wang
H. Williams
K. Yasuda
B. Zhong

Graduate Students
K. Annu
R.J. Autry
A. Cozzarolo
A. Crumby
S. Ganguly
J. Hu
C. Jiang
N. Keeling
A. Zhao
C. Zou

Clinical PK Lab and Pgx
A. Molinelli, PhD, PK Clin Lab Director
K. Effinger
L. Howell
S. Johns
E. McClure
E. Melton
C. Rose
C. Suggs
Kris Crews, PharmD, Lab Director
Kelly Caudle, PharmD, CPIC Proj Leader
Cyrine Haidar, PharmD, Coord-Clin, Pgx
Roseann Gammal, PharmD

Computer Specialists - Sci
Nancy Kornegay, Director, Pharm
Sci Informatics
Austin Springer, Sr. DB Analyst
Andrey Matlin, DB Analyst
Colton Smith, Info Analyst
Wenjian Yang, Bio Analyst

Sr. Clinical Staff Pharmacists
Monica Bant, PharmD
Susan Carr, PharmD
Shane Marshall, PharmD
Gayle Westmoreland, PharmD
Cheri Wilkerson, PharmD

Clinical Pharmacy Specialists
Liz Alford, Pharm D
PJ Barker, PharmD
Allison Bragg, PharmD
Andy Christensen, PharmD
Richard Clark, PharmD
Shane Cross, PharmD
Clay Daniels, PharmD
Melissa Quinn, PharmD
Hope Swanson, PharmD
Deborah Ward, PharmD

Invest. Studies Pharm
Robbin Christensen, DPh
Linda Marden, DPh
Julie Richardson, PharmD
Chris Scobey, PharmD
Camille Smith, PharmD

Specialty Infusion Nurses
Nichole Lewis, BSN, RN, CPN
Mary Reynolds, BSN, RN
Ellie Thornton, BSN, RN

Student Interns
M. Buckley
S. Duffey
K. Heintz
J. King
B. McGlaughin
P. Metcalf
S. Patel
T. Verstak
R. Wilbert

Clinical Pharmacists
C. Askins
J. Bryant
M. Coleman
H. Danzi
N. DeRenzo
D. Ethridge
J. Evans
L. Gallimore
A. Harris
T. Jacobs
J. Kemper
J. Knych
C. Longserre
J. Mason
A. McCormick
T. Mills
J. Moore
T. Nason
T. Nguyen
T. Peery
J. Quackenbush
L. Schiff
K. Smith
T. Todd
D. Trone
D. Ulrich
E. Wilson
M. Wilson
C. Yeh

Clinical Pharmacy Residents
P. Carpiniello
K. Hyman
A. Lambrix
C. Thomas

Pharmacy Technicians
T. Akins
D. Black
L. Bowman
R. Branum
M. Brittmon
S. Brittmon
D. Brooks
M. Brown
T. Bryant
D. Calhoun
L. Carlton
H. Cash
R. Chapman
N. Cole
R. Connors
J. Cooper
P. Dorse
L. Gallimore
R. Garrett
C. Greer
C. Henderson
T. Henderson
A. Hunley
K. Hunter
P. Hunter
C. Johnson
D. Lewis
A. London
N. Lundy
B. Macklin
A. Martin
K. McClelland
K. McRae
E. McVey
S. Milan
C. Owens
N. Sims
T. Smith
L. Sugg
S. Summerhill
P. Taylor
W. Taylor III
D. White
L. Wild
S. Williams

Computer Specialists – Srv
Bruce Girdler, Coord Ph Sys
Murad Hasan, Sr. Database Analyst
Tim Hill, Ph Inf Spec II/ 340B Coord.
Elaine King, Ph Inf Spec I
Chris Moon, Ph Inf Spec I
Alex Rodriguez, Ph Inf Spec II

2.14.2018